Arcturus Therapeutics Holdings INC

Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy for cystic fibrosis, ARCT-032.

Arcturus Therapeutics stockholders re-elected the board of directors and ratified the appointment of Deloitte as auditor.

Arcturus Therapeutics announced its fourth quarter and fiscal year 2025 financial results, highlighting progress in its rare disease pipeline and an extended cash runway.

Arcturus Therapeutics announced the mutual separation of CFO Andy Sassine and the appointment of Controller Joe Roberts as interim principal financial and accounting officer.

Arcturus Therapeutics announced its third quarter 2025 financial results, highlighted by encouraging cystic fibrosis trial data, strategic cost reductions, and a delay in its U.S. COVID-19 vaccine BLA filing.

Arcturus Therapeutics announced encouraging interim Phase 2 results for its cystic fibrosis therapy ARCT-032 but faced a significant delay and new data requirements for its KOSTAIVE COVID-19 vaccine BLA submission to the FDA.

Arcturus Therapeutics reported a significant revenue decline in Q3 2025, primarily due to its COVID-19 vaccine transitioning to commercial phase, while facing an FDA delay for its KOSTAIVE BLA submission and ongoing material weakness in internal controls.

Arcturus Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses, as its COVID-19 vaccine KOSTAIVE received EU marketing authorization and key therapeutic programs advanced.

Arcturus Therapeutics announces its Q1 2025 financial results, emphasizing the commercialization of KOSTAIVE and progress in its mRNA therapeutics pipeline.

Arcturus Therapeutics announced its Q3 2024 financial results, highlighted by the commercial launch of its self-amplifying mRNA COVID-19 vaccine in Japan and progress in its clinical programs.

Arcturus Therapeutics announced its second quarter 2024 financial results, highlighting progress in its mRNA vaccine and therapeutic programs, including a significant increase in collaboration revenue.

Arcturus Therapeutics reported a net loss for Q1 2024, while highlighting progress in its mRNA vaccine and therapeutic programs, including key updates on its collaboration with CSL Seqirus.

Arcturus Therapeutics transitions to a commercial-stage company with KOSTAIVE sales in Japan and advances its mRNA vaccine and therapeutic pipeline.

Arcturus Therapeutics Holdings Inc.'s 10-K filing details stock ownership, insider trading policies, and financial performance, highlighting its focus on mRNA medicines and strategic collaborations.

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes acquired 15,000 stock options with an exercise price of $7.30, vesting over one year.

Arcturus Therapeutics Holdings Inc. director Peter C. Farrell was granted stock options for 15,000 shares.

Arcturus Therapeutics Holdings Inc. director James F. Barlow acquired 15,000 stock options with an exercise price of $7.30, vesting monthly over one year.

Arcturus Therapeutics Holdings Inc. director John Markels acquired stock options as part of his annual grant, with vesting over one year.

Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted stock options for 15,000 shares.

Arcturus Therapeutics Holdings Inc. reports that Director Magda Marquet acquired 15,000 stock options.

Arcturus Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and auditor ratification.

Arcturus Therapeutics announces its 2025 annual stockholders meeting to be held virtually on June 6, 2025, featuring director elections, executive compensation approval, and auditor ratification.

Arcturus Therapeutics announces its 2024 annual meeting of stockholders to be held virtually on June 14, 2024, featuring proposals including director elections and an amendment to the equity incentive plan.

ARK Investment Management LLC and Catherine D. Wood have jointly filed a Schedule 13G, reporting beneficial ownership of 10.37% of Arcturus Therapeutics Holdings Inc. common stock as of April 30, 2026.

The Vanguard Group has reported zero beneficial ownership in Arcturus Therapeutics Holdings Inc. following an internal realignment.

Balyasny Asset Management and its affiliates have reported a complete divestment of their beneficial ownership in Arcturus Therapeutics Holdings Inc.

ARK Investment Management LLC and Catherine D. Wood filed an Amendment No. 9 on Schedule 13G, disclosing a 9.19% beneficial ownership in Arcturus Therapeutics Holdings Inc.

Federated Hermes, Inc. and related entities have filed an amended Schedule 13G, reporting beneficial ownership of 11.63% of Arcturus Therapeutics Holdings Inc. common stock.

Balyasny Asset Management L.P. and its affiliates have disclosed a beneficial ownership of 8.04% in Arcturus Therapeutics Holdings Inc., holding 2,183,985 shares.